GI of flavour 1 was 27.3 ± 4.8mg/dl while flavour 2 was 36.7 ± 4.4mg/dl. They also measured the glycaemic index (GI) of both products, which were below 55 and therefore classified as low GI. Researchers found that the GR of supplement (flavour 1) was 16.4 ± 2.6mg/dl, while that of supplement (flavour 2) was 25.7 ± 2.3mg/dl. Glycaemic response (GR) was measured using blood samples collected before and after test food consumption (-5), 0, 15, 30, 45, 60, 90 and 120 minutes. They then consumed the test food (Celevida) for one day in a random order (flavour 1 - 46g in 300 mL of milk or flavour 2 - 38g in 345 mL of milk) Participants were told to consume a reference food (27.5 g of monohydrate glucose dissolved in 100 mL of water) for three days. Clinical studiesĬelevida had been clinically tested on 15 overweight or obese Indian subjects aged 18 to 45 years.
The firm expressed that the drinks had gone through a taste test with more than 300 diabetic and prediabetic consumers. The drink is currently available in two flavours, Kesar Elachi and Chocolate. It is formulated with soy, ragi and gram flour which are considered a complete protein as it has all the essential amino acids and other macronutrients. This way, it helps manage blood sugar spikes through steady energy release.Ĭelevida is also high in MUFA which helps in lowering triglycerides in diabetes patients and can improve glycaemic control by lowering fasting plasma glucose levels and post prandial blood glucose. It contains a high protein level between 28 to 30% depending on flavour, high fibre levels (12 to 18%) and slowly digested carbohydrates, which will support in managing the postprandial blood glucose response and satiety.Ĭelevida is formulated with fibersol, a modified maltodextrin with glucose linkages that are more resistant to digestive enzyme amylase.ĭue to the slower digestion of glucose from fibersol, it has a longer retention time in the gastrointestinal tract which give fibersol a lower glycaemic index (GI) and help slowly release glucose in the body. Nutrition is shown in various studies to improve clinical outcomes as well as quality-of-life in several disease conditions.” Regulate blood glucoseĬelevida was designed for people with diabetes as well as non-diabetics intending to manage their weight. The company’s chief executive officer of branded markets (India and emerging markets), M V Ramana told NutraIngredients-Asia the move into nutrition drinks was “ part of our overall strategy to strengthen our business portfolio for high-growth therapy areas. Changing habits of diet and a sedentary lifestyle have contributed to the rise of diabetes in the growing population. The drink is said to help manage blood glucose levels among Indian patients.ĭiabetes is a growing challenge in India with 73 million people suffering from diabetes, and 80 million people with pre-diabetes, and the country is expected to have the world’s largest diabetes population by 2035.
China: Probiotic supplements in e-commerce.Digestion and immunity probiotic supplements in e-commerce.Explained: The US e-commerce probiotic supplements market.Probiotic supplements: Global e-commerce 2018-2020, forecast for 2021.The gut-brain axis: Psychobiotic opportunity in 25 countriese.
0 kommentar(er)
